DALLAS / Aug 09, 2023 / Business Wire / Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the second quarter ended June 30, 2023.
“During the second quarter, we negotiated ten new contracts with Medicare Advantage payors, increased our clinical staff with 203 net new full-time nursing hires, and continued to outperform the industry average with a 30-day hospital readmission rate that is 370 basis points better than the national average,” said Enhabit’s President and Chief Executive Officer, Barb Jacobsmeyer. “While we continue to make progress with our strategic initiatives, the pace of the progress has not been fast enough in 2023 to meet our initial guidance. We remain confident our teams’ relentless efforts to retain staff, manage costs, and deliver high-quality care will enhance our value long term.”
QUARTERLY PERFORMANCE - CONSOLIDATED
RECENT COMPANY HIGHLIGHTS
FINANCIAL RESULTS
Consolidated
($ in millions, except per share data) | Q2 | '23 vs. '22 | |||||||
| 2023 | 2022 | |||||||
Home health net service revenue | $ | 213.8 | $ | 220.2 | (2.9)% | ||||
Hospice net service revenue |
| 48.5 |
| 47.8 | 1.5% | ||||
Total net service revenue | $ | 262.3 | $ | 268.0 | (2.1)% | ||||
| % of Revenue |
| % of Revenue |
|
| ||||
Cost of services | 51.7% | $ | (135.5) | 48.6% | $ | (130.3) | 4.0% | ||
Gross margin | 48.3% |
| 126.8 | 51.4% |
| 137.7 | (7.9)% | ||
General & administrative expenses | 39.2% |
| (102.7) | 36.1% |
| (96.7) | 6.2% | ||
Operating expenses | 90.8% |
| (238.2) | 84.7% |
| (227.0) | 4.9% | ||
Other income |
| (0.1) |
| — |
| ||||
Equity earnings / noncontrolling interest |
| 0.3 |
| 0.7 |
| ||||
Adjusted EBITDA | $ | 23.9 | $ | 40.3 | (40.7)% | ||||
Adjusted EBITDA margin |
| 9.1% |
| 15.0% |
| ||||
Reported Diluted EPS | $ | (1.49) | $ | 0.41 | (467.7)% | ||||
Adjusted EPS | $ | 0.04 | $ | 0.47 | (91.5)% | ||||
The continued shift to more non-episodic admissions in home health and the resumption of sequestration reduced consolidated net service revenue and Adjusted EBITDA $10.5 million year over year.
Adjusted EBITDA decreased year over year primarily due to the continued shift to more non-episodic admissions in home health, incremental costs associated with being a stand-alone company, and the resumption of sequestration.
SEGMENT RESULTS
Home health
($ in millions) | Q2 | '23 vs. '22 | |||||
|
| 2023 |
| 2022 | |||
Net service revenue | $ | 213.8 | $ | 220.2 | (2.9)% | ||
Cost of services |
| 111.4 |
| 108.8 | 2.4% | ||
Gross margin |
| 47.9 % |
| 50.6 % |
| ||
General & administrative expenses | $ | 59.4 | $ | 57.8 | 2.8% | ||
Other income | $ | (0.1) | $ | — |
| ||
Equity earnings / noncontrolling interest | $ | 0.3 | $ | 0.6 | (50.0)% | ||
Adjusted EBITDA | $ | 42.8 | $ | 53.0 | (19.2)% | ||
% Adj. EBITDA margin |
| 20.0 % |
| 24.1 % |
| ||
Operational metrics (Actual Amounts) |
|
|
| ||||
Starts of care |
|
|
| ||||
Episodic admissions |
| 32,628 |
| 36,106 | (9.6)% | ||
Non-episodic admissions |
| 18,347 |
| 13,293 | 38.0% | ||
Total admissions |
| 50,975 |
| 49,399 | 3.2% | ||
Same-store total admissions growth |
|
| 1.7% | ||||
Episodic recertifications |
| 23,788 |
| 25,993 | (8.5)% | ||
Non-episodic recertifications |
| 9,554 |
| 6,447 | 48.2% | ||
Total recertifications |
| 33,342 |
| 32,440 | 2.8% | ||
Same-store total recertifications growth |
|
| 2.2% | ||||
Total starts of care |
| 84,317 |
| 81,839 | 3.0% | ||
Completed episodes |
| 56,808 |
| 62,691 | (9.4)% | ||
Revenue per episode | $ | 2,913 | $ | 2,972 | (2.0)% | ||
Visits per episode |
| 14.6 |
| 15.0 | (2.7)% | ||
Total visits |
| 1,205,865 |
| 1,217,447 | (1.0)% | ||
Non-episodic visits |
| 377,214 |
| 275,679 | 36.8% | ||
Cost per visit | $ | 91 | $ | 88 | 3.4% | ||
The year-over-year decrease in revenue was due primarily to the continued payor mix shift to more non-episodic admissions and the resumption of sequestration. Revenue per episode decreased year over year primarily due to the resumption of sequestration and patient mix.
Adjusted EBITDA decreased year over year primarily due to the continued payor mix shift to more non-episodic admissions, the resumption of sequestration, and increased general and administrative expenses associated with new stores. Cost per visit increased year-over-year primarily due to increased contract labor, merit and market rate increases for clinical staff, and increased costs associated with employee group medical claims partially offset by improved clinical productivity.
Hospice
($ in millions) | Q2 | '23 vs. '22 | |||||
| 2023 | 2022 | |||||
Net service revenue | $ | 48.5 | $ | 47.8 | 1.5 % | ||
Cost of services |
| 24.1 |
| 21.5 | 12.1 % | ||
Gross margin |
| 50.3 % |
| 55.0 % |
| ||
General & administrative expenses | $ | 16.1 | $ | 15.5 | 3.9 % | ||
Equity earnings / noncontrolling interest | $ | — | $ | 0.1 |
| ||
Adjusted EBITDA | $ | 8.3 | $ | 10.7 | (22.4) % | ||
% Adj. EBITDA margin |
| 17.1 % |
| 22.4 % |
| ||
Operational metrics (Actual Amounts) |
|
|
| ||||
Total admissions |
| 2,837 |
| 2,835 | 0.1 % | ||
Same-store total admissions growth |
|
| (4.1) % | ||||
Patient days |
| 311,465 |
| 313,718 | (0.7) % | ||
Discharged average length of stay |
| 108 |
| 109 | (0.9) % | ||
Average daily census |
| 3,423 |
| 3,447 | (0.7) % | ||
Revenue per day | $ | 156 | $ | 152 | 2.6 % | ||
Cost per day | $ | 77 | $ | 69 | 11.6 % | ||
Net service revenue increased year over year primarily due to increased Medicare reimbursement rates.
Adjusted EBITDA decreased year over year primarily due to higher cost of services resulting from increased labor costs. Cost per day increased year over year primarily due to increased labor costs resulting from the implementation of the new case management model, including costs associated with dedicated on-call and triage nurses.
TAX MATTERS AGREEMENT
Enhabit also announced today that it is undertaking steps to attempt to satisfy the conditions in its Tax Matters Agreement (“TMA”), dated June 30, 2022, with Encompass Health Corporation relating to certain transactions involving the Company. The conditions in the TMA include securing a tax opinion of legal counsel, satisfactory to Encompass Health in its sole and absolute discretion, that the actions taken by Enhabit would not jeopardize the tax-free treatment of the spin-off of Enhabit.
Upon satisfaction of these conditions, the Enhabit board, with the assistance of independent advisors, intends to launch a strategic alternatives process. As part of any such process, the board expects it would consider a wide range of options for the company including, among other things, a potential sale, merger or other strategic transaction. There can be no assurance that the conditions in the TMA will be satisfied, that Enhabit will initiate such a process, or if launched, that a process would result in Enhabit pursuing a particular transaction or other strategic outcome.
GUIDANCE
The Company revised its full-year 2023 guidance as follows:
($ in millions, except per share data) |
| ||
Full-Year 2023 | 2023 Original Guidance | 2023 Revised Guidance | |
Net Service Revenue | $1,110 to $1,140 | $1,057 to $1,065 | |
Adjusted EBITDA | $125 to $140 | $100 to $107 | |
Adjusted EPS | $0.50 to $0.89 | $0.28 to $0.46 | |
For additional considerations regarding the Company’s 2023 guidance ranges, see the supplemental information posted on the Company’s website at http://investors.ehab.com.
CONFERENCE CALL INFORMATION
The Company will host an investor conference call at 10 AM Eastern Time on August 10, 2023 to discuss its results for the second quarter of 2023. To access the live call by phone, dial toll-free (888) 660-6150 or international (929) 203-0843; the conference ID is 5248158. A simultaneous webcast of the call, along with supplemental information, may be accessed by visiting https://events.q4inc.com/attendee/923162031. Following the call, a replay will be available at Enhabit’s investor website.
ABOUT ENHABIT HOME HEALTH & HOSPICE
Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit’s team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 255 home health locations and 108 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit ehab.com.
OTHER INFORMATION
Note regarding presentation of non-GAAP financial measures
The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, leverage ratios, adjusted EPS, and adjusted free cash flow. See “Reconciliations of Non-GAAP Financial Measures” for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP.
The Company is unable to reconcile the guidance for Adjusted EBITDA and adjusted EPS to their corresponding GAAP measures without unreasonable effort due to the inherent difficulty in predicting, with reasonable certainty, the future impact of items that are outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Accordingly, the Company relies on the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K. Such items include, but are not limited to, gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); and items related to corporate and facility restructurings. For the same reasons, the Company is unable to address the probable significance of the unavailable information.
Note regarding reconciliations of non-GAAP financial measures
This press release contains the reconciliations of non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Such non-GAAP financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies.
Note regarding presentation of same-store comparisons
The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company’s results of operations.
Enhabit, Inc. and Subsidiaries Condensed Consolidated Statements of Income (Unaudited) | |||||||||||||
Three Months Ended |
| Six Months Ended | |||||||||||
|
| 2023 |
|
|
| 2022 |
|
| 2023 |
|
|
| 2022 |
| ($ in millions, except per share data) | ||||||||||||
Net service revenue | $ | 262.3 |
|
| $ | 268.0 |
| $ | 527.4 |
|
| $ | 542.3 |
Cost of service, excluding depreciation and amortization |
| 135.5 |
|
|
| 130.3 |
|
| 268.1 |
|
|
| 260.0 |
General and administrative expenses |
| 107.8 |
|
|
| 102.2 |
|
| 218.3 |
|
|
| 202.9 |
Depreciation and amortization |
| 7.7 |
|
|
| 8.2 |
|
| 15.5 |
|
|
| 16.7 |
Impairment of goodwill |
| 85.8 |
|
|
| — |
|
| 85.8 |
|
|
| — |
Operating income |
| (74.5 | ) |
|
| 27.3 |
|
| (60.3 | ) |
|
| 62.7 |
Interest expense and amortization of debt discounts and fees |
| 10.3 |
|
|
| 0.1 |
|
| 19.8 |
|
|
| 0.1 |
Other income |
| (0.1 | ) |
|
| — |
|
| (0.1 | ) |
|
| — |
(Loss) income before income taxes and noncontrolling interests |
| (84.7 | ) |
|
| 27.2 |
|
| (80.0 | ) |
|
| 62.6 |
Income tax (benefit) expense |
| (10.6 | ) |
|
| 6.4 |
|
| (9.1 | ) |
|
| 15.1 |
Net (loss) income |
| (74.1 | ) |
|
| 20.8 |
|
| (70.9 | ) |
|
| 47.5 |
Less: Net income attributable to noncontrolling interests |
| 0.3 |
|
|
| 0.7 |
|
| 0.8 |
|
|
| 1.3 |
Net (loss) income attributable to Enhabit, Inc. | $ | (74.4 | ) |
| $ | 20.1 |
| $ | (71.7 | ) |
| $ | 46.2 |
|
|
|
|
|
|
|
| ||||||
Weighted average common shares outstanding: |
|
|
|
|
|
|
| ||||||
Basic |
| 49.8 |
|
|
| 49.6 |
|
| 49.8 |
|
|
| 49.6 |
Diluted |
| 49.8 |
|
|
| 49.6 |
|
| 49.8 |
|
|
| 49.6 |
|
|
|
|
|
|
|
| ||||||
(Loss) earnings per common share: |
|
|
|
|
|
|
| ||||||
Basic (loss) earnings per share attributable to Enhabit, Inc. common stockholders | $ | (1.49 | ) |
| $ | 0.41 |
| $ | (1.44 | ) |
| $ | 0.93 |
Diluted (loss) earnings per share attributable to Enhabit, Inc. common stockholders | $ | (1.49 | ) |
| $ | 0.41 |
| $ | (1.44 | ) |
| $ | 0.93 |
Enhabit, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited) | |||||
|
|
|
| ||
| June 30, |
| December 31, | ||
| ($ in millions) | ||||
Assets |
|
|
| ||
Current assets: |
|
|
| ||
Cash and cash equivalents | $ | 34.4 |
| $ | 22.9 |
Restricted cash |
| 2.1 |
|
| 4.3 |
Accounts receivable |
| 147.6 |
|
| 149.6 |
Income tax receivable |
| 3.9 |
|
| 11.4 |
Prepaid expenses and other current assets |
| 11.6 |
|
| 23.6 |
Total current assets |
| 199.6 |
|
| 211.8 |
Property and equipment, net |
| 18.5 |
|
| 20.4 |
Operating lease right-of-use assets |
| 49.3 |
|
| 42.0 |
Goodwill |
| 1,061.7 |
|
| 1,144.8 |
Intangible assets, net |
| 91.2 |
|
| 102.6 |
Other long-term assets |
| 5.9 |
|
| 5.2 |
Total assets | $ | 1,426.2 |
| $ | 1,526.8 |
Liabilities and Stockholders’ Equity |
|
|
| ||
Current liabilities: |
|
|
| ||
Current portion of long-term debt | $ | 22.5 |
| $ | 23.1 |
Current operating lease liabilities |
| 11.7 |
|
| 14.0 |
Accounts payable |
| 5.4 |
|
| 3.8 |
Accrued payroll |
| 32.8 |
|
| 35.5 |
Refunds due patients and other third-party payors |
| 7.1 |
|
| 8.3 |
Accrued medical insurance |
| 8.2 |
|
| 7.5 |
Other current liabilities |
| 35.8 |
|
| 40.7 |
Total current liabilities |
| 123.5 |
|
| 132.9 |
Long-term debt, net of current portion |
| 539.3 |
|
| 560.0 |
Long-term operating lease liabilities |
| 37.5 |
|
| 28.1 |
Deferred income tax liabilities |
| 18.1 |
|
| 28.6 |
Other long-term liabilities |
| 0.6 |
|
| 1.9 |
|
| 719.0 |
|
| 751.5 |
Commitments and contingencies |
|
|
| ||
Redeemable noncontrolling interests |
| 5.1 |
|
| 5.2 |
Stockholders’ equity: |
|
|
| ||
Enhabit, Inc. stockholders’ equity: |
| 675.2 |
|
| 741.7 |
Noncontrolling interests |
| 26.9 |
|
| 28.4 |
Total stockholders’ equity |
| 702.1 |
|
| 770.1 |
Total liabilities and stockholders’ equity | $ | 1,426.2 |
| $ | 1,526.8 |
Enhabit, Inc. and Subsidiaries Condensed Consolidated Cash Flows (Unaudited) | |||||||
|
| ||||||
| Six Months Ended | ||||||
|
| 2023 |
|
|
| 2022 |
|
| ($ in millions) | ||||||
Cash flows from operating activities: |
|
|
| ||||
Net (loss) income | $ | (70.9 | ) |
| $ | 47.5 |
|
Adjustments to reconcile net (loss) income to net cash provided by operating activities— |
|
|
| ||||
Depreciation and amortization |
| 15.5 |
|
|
| 16.7 |
|
Amortization of debt related costs |
| 0.5 |
|
|
| — |
|
Impairment of goodwill |
| 85.8 |
|
|
| — |
|
Stock-based compensation |
| 4.1 |
|
|
| 2.5 |
|
Deferred tax benefit |
| (11.0 | ) |
|
| (1.4 | ) |
Other, net |
| 0.9 |
|
|
| (0.6 | ) |
Changes in assets and liabilities, net of acquisitions— |
|
|
| ||||
Accounts receivable |
| 1.9 |
|
|
| 13.4 |
|
Prepaid expenses and other assets |
| 19.2 |
|
|
| (2.7 | ) |
Accounts payable |
| 1.5 |
|
|
| (0.8 | ) |
Accrued payroll |
| (2.6 | ) |
|
| 6.2 |
|
Other liabilities |
| (5.7 | ) |
|
| (5.8 | ) |
Net cash provided by operating activities |
| 39.2 |
|
|
| 75.0 |
|
Cash flows from investing activities: |
|
|
| ||||
Acquisition of businesses, net of cash acquired |
| (2.8 | ) |
|
| — |
|
Purchases of property and equipment |
| (1.7 | ) |
|
| (4.5 | ) |
Other, net |
| 0.5 |
|
|
| 1.0 |
|
Net cash used in investing activities |
| (4.0 | ) |
|
| (3.5 | ) |
Cash flows from financing activities: |
|
|
| ||||
Principal borrowings on term loan |
| — |
|
|
| 400.0 |
|
Principal payments on term loan |
| (10.0 | ) |
|
| — |
|
Principal payments on debt |
| — |
|
|
| (0.4 | ) |
Borrowings on revolving credit facility |
| — |
|
|
| 170.0 |
|
Payments on revolving credit facility |
| (10.0 | ) |
|
| — |
|
Principal payments under finance lease obligations |
| (1.8 | ) |
|
| (2.6 | ) |
Debt issuance costs |
| (1.1 | ) |
|
| (4.4 | ) |
Distributions paid to noncontrolling interests of consolidated affiliates |
| (2.5 | ) |
|
| (0.7 | ) |
Contributions from Encompass |
| — |
|
|
| 59.8 |
|
Distributions to Encompass |
| — |
|
|
| (654.9 | ) |
Contributions from noncontrolling interests of consolidated affiliates |
| — |
|
|
| 7.4 |
|
Other |
| (0.5 | ) |
|
| — |
|
Net cash used in financing activities |
| (25.9 | ) |
|
| (25.8 | ) |
Increase in cash, cash equivalents, and restricted cash |
| 9.3 |
|
|
| 45.7 |
|
Cash, cash equivalents, and restricted cash at beginning of year |
| 27.2 |
|
|
| 8.0 |
|
Cash, cash equivalents, and restricted cash at end of period | $ | 36.5 |
|
| $ | 53.7 |
|
Enhabit, Inc. and Subsidiaries Supplemental Information Adjusted Earnings Per Share | |||||||||||||
| Three Months Ended |
| Six Months Ended | ||||||||||
|
| 2023 |
|
|
| 2022 |
|
| 2023 |
|
|
| 2022 |
Earnings per share, as reported | $ | (1.49 | ) |
| $ | 0.41 |
| $ | (1.44 | ) |
| $ | 0.93 |
Adjustments, net of tax: |
|
|
|
|
|
|
| ||||||
Impairment of goodwill |
| 1.50 |
|
|
| — |
|
| 1.50 |
|
|
| — |
Unusual or nonrecurring items that are not typical of ongoing operations(1) |
| 0.03 |
|
|
| 0.06 |
|
| 0.07 |
|
|
| 0.09 |
Income tax adjustments(2) |
| — |
|
|
| — |
|
| 0.01 |
|
|
| — |
Adjusted earnings per share(3) | $ | 0.04 |
|
| $ | 0.47 |
| $ | 0.14 |
|
| $ | 1.02 |
(1) | Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism defense; in 2022, they include costs associated with the strategic alternatives review. |
(2) | Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. |
(3) | Adjusted EPS may not sum due to rounding. |
Enhabit, Inc. and Subsidiaries Supplemental Information Adjusted Earnings Per Share | ||||||||||||||||||
| Q2 QTD | |||||||||||||||||
| 2023 | |||||||||||||||||
|
| Adjustments |
| |||||||||||||||
| As Reported |
| Impairment of |
| Unusual or nonrecurring items that are not typical of ongoing operations |
| Income Tax |
| As Adjusted | |||||||||
| ($ in millions, except per share data) | |||||||||||||||||
Adjusted EBITDA(1) | $ | 23.9 |
|
| $ | — |
|
| $ | — |
|
| $ | — |
| $ | 23.9 |
|
Impairment of goodwill |
| (85.8 | ) |
|
| 85.8 |
|
|
| — |
|
| — |
| — |
| ||
Interest expense and amortization of debt discounts and fees |
| (10.3 | ) |
|
|
|
| — |
|
|
| — |
| (10.3 | ) | |||
Depreciation and amortization |
| (7.7 | ) |
|
| — |
|
|
| — |
|
|
| — |
|
| (7.7 | ) |
Unusual or nonrecurring items that are not typical of ongoing operations(2) |
| (2.6 | ) |
|
| — |
|
|
| 2.6 |
|
|
| — |
|
| — |
|
Stock-based compensation |
| (2.6 | ) |
|
| — |
|
|
| — |
|
|
| — |
|
| (2.6 | ) |
Gain on disposal or impairment of assets |
| 0.1 |
|
|
| — |
|
|
| — |
|
|
| — |
|
| 0.1 |
|
Net loss before income tax expense, including noncontrolling interests |
| (85.0 | ) |
|
| 85.8 |
|
|
| 2.6 |
|
|
| — |
|
| 3.4 |
|
Income tax benefit (expense) |
| 10.6 |
|
|
| (11.1 | ) |
|
| (1.0 | ) |
|
| 0.1 |
|
| (1.4 | ) |
Net (loss) income attributable to Enhabit | $ | (74.4 | ) |
| $ | 74.7 |
|
| $ | 1.6 |
|
| $ | 0.1 |
| $ | 2.0 |
|
Diluted earnings per share(4) | $ | (1.49 | ) |
| $ | 1.50 |
|
| $ | 0.03 |
|
| $ | — |
| $ | 0.04 |
|
Diluted shares |
| 49.8 |
|
|
|
|
|
|
|
|
| 49.8 |
| |||||
(1) | See reconciliation of net income to Adjusted EBITDA below. |
(2) | Unusual or nonrecurring items in 2023 include costs associated with non-routine litigation and shareholder activism defense. |
(3) | Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. |
(4) | Adjusted EPS may not sum due to rounding. |
| Enhabit, Inc. and Subsidiaries Supplemental Information Adjusted Earnings Per Share | |||||||||||
| Q2 QTD | ||||||||||
| 2022 | ||||||||||
|
|
| Adjustments |
|
| ||||||
| As Reported |
| Unusual or |
| As Adjusted | ||||||
| ($ in millions, except per share data) | ||||||||||
Adjusted EBITDA(1) | $ | 40.3 |
|
| $ | — |
|
| $ | 40.3 |
|
Depreciation and amortization |
| (8.2 | ) |
|
| — |
|
|
| (8.2 | ) |
Unusual or nonrecurring items that are not typical of ongoing operations(2) |
| (4.1 | ) |
|
| 4.1 |
|
|
| — |
|
Stock-based compensation |
| (1.2 | ) |
|
| — |
|
|
| (1.2 | ) |
Stock-based compensation included in overhead allocation |
| (0.6 | ) |
|
| — |
|
|
| (0.6 | ) |
Gain on disposal or impairment of assets |
| 0.4 |
|
|
| — |
|
|
| 0.4 |
|
Interest expense and amortization of debt discounts and fees |
| (0.1 | ) |
|
| — |
|
|
| (0.1 | ) |
|
|
|
|
|
| ||||||
Income before income tax expense |
| 26.5 |
|
|
| 4.1 |
|
|
| 30.6 |
|
Provision for income tax expense |
| (6.4 | ) |
|
| (1.0 | ) |
|
| (7.4 | ) |
Net income attributable to Enhabit | $ | 20.1 |
|
| $ | 3.1 |
|
| $ | 23.2 |
|
Diluted earnings per share(3) | $ | 0.41 |
|
| $ | 0.06 |
|
| $ | 0.47 |
|
Diluted shares used in calculation |
| 49.6 |
|
|
|
|
| 49.6 |
| ||
(1) | See reconciliation of net income to Adjusted EBITDA below. |
(2) | Unusual or nonrecurring items in 2022 include costs associated with the strategic alternatives review. |
(3) | Adjusted EPS may not sum due to rounding. |
Enhabit, Inc. and Subsidiaries Supplemental Information Adjusted Earnings Per Share | ||||||||||||||||||
| YTD | |||||||||||||||||
| 2023 | |||||||||||||||||
|
|
| Adjustments |
|
| |||||||||||||
| As Reported |
| Impairment of |
| Unusual or |
| Income Tax |
| As Adjusted | |||||||||
| ($ in millions, except per share data) | |||||||||||||||||
Adjusted EBITDA(1) | $ | 49.2 |
|
| $ | — |
|
| $ | — |
|
| $ | — |
| $ | 49.2 |
|
Impairment of goodwill |
| (85.8 | ) |
|
| 85.8 |
|
|
| — |
|
|
| — |
|
| — |
|
Interest expense and amortization of debt discounts and fees |
| (19.8 | ) |
|
| — |
|
|
| — |
|
|
| — |
|
| (19.8 | ) |
Depreciation and amortization |
| (15.5 | ) |
|
| — |
|
|
| — |
|
|
| — |
|
| (15.5 | ) |
Unusual or nonrecurring items that are not typical of ongoing operations(2) |
| (4.9 | ) |
|
| — |
|
|
| 4.9 |
|
|
| — |
|
| — |
|
Stock-based compensation |
| (4.1 | ) |
|
| — |
|
|
| — |
|
|
| — |
|
| (4.1 | ) |
Gain on disposal or impairment of assets |
| 0.1 |
|
|
| — |
|
|
| — |
|
|
| — |
|
| 0.1 |
|
Net loss before income taxes, including noncontrolling interests |
| (80.8 | ) |
|
| 85.8 |
|
|
| 4.9 |
|
|
| — |
|
| 9.9 |
|
Income tax benefit (expense) |
| 9.1 |
|
|
| (11.1 | ) |
|
| (1.6 | ) |
|
| 0.5 |
|
| (3.1 | ) |
Net (loss) income attributable to Enhabit | $ | (71.7 | ) |
| $ | 74.7 |
|
| $ | 3.3 |
|
| $ | 0.5 |
| $ | 6.8 |
|
Diluted earnings per share(4) | $ | (1.44 | ) |
| $ | 1.50 |
|
| $ | 0.07 |
|
| $ | 0.01 |
| $ | 0.14 |
|
Diluted shares |
| 49.8 |
|
|
|
|
|
|
|
|
| 49.8 |
| |||||
(1) | See reconciliation of net income to Adjusted EBITDA below. |
(2) | Unusual or nonrecurring items in 2023 include costs associated with non-routine litigation and shareholder activism defense. |
(3) | Income tax adjustments include the effect of permanent book-tax differences attributable to stock-based compensation. |
(4) | Adjusted EPS may not sum due to rounding. |
Enhabit, Inc. and Subsidiaries Supplemental Information Adjusted Earnings Per Share | |||||||||||
|
| ||||||||||
| YTD | ||||||||||
| 2022 | ||||||||||
|
|
| Adjustments |
|
| ||||||
| As Reported |
| Unusual or |
| As Adjusted | ||||||
| ($ in millions, except per share data) | ||||||||||
Adjusted EBITDA(1) | $ | 87.3 |
|
| $ | — |
|
| $ | 87.3 |
|
Depreciation and amortization |
| (16.7 | ) |
|
| — |
|
|
| (16.7 | ) |
Unusual or nonrecurring items that are not typical of ongoing operations(2) |
| (6.1 | ) |
|
| 6.1 |
|
|
| — |
|
Stock-based compensation |
| (2.5 | ) |
|
| — |
|
|
| (2.5 | ) |
Stock-based compensation included in overhead allocation |
| (1.1 | ) |
|
| — |
|
|
| (1.1 | ) |
Gain on disposal or impairment of assets |
| 0.5 |
|
|
| — |
|
|
| 0.5 |
|
Interest expense and amortization of debt discounts and fees |
| (0.1 | ) |
|
| — |
|
|
| (0.1 | ) |
Income before income tax expense |
| 61.3 |
|
|
| 6.1 |
|
|
| 67.4 |
|
Provision for income tax expense |
| (15.1 | ) |
|
| (1.5 | ) |
|
| (16.6 | ) |
Net income attributable to Enhabit | $ | 46.2 |
|
| $ | 4.6 |
|
| $ | 50.8 |
|
Diluted earnings per share(3) | $ | 0.93 |
|
| $ | 0.09 |
|
| $ | 1.02 |
|
Diluted shares used in calculation |
| 49.6 |
|
|
|
|
| 49.6 |
| ||
(1) | See reconciliation of net income to Adjusted EBITDA below. |
(2) | Unusual or nonrecurring items in 2022 include costs associated with the strategic alternatives review. |
(3) | Adjusted EPS may not sum due to rounding. |
Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Net Income to Adjusted EBITDA | |||||||||||||||
|
|
|
| ||||||||||||
| Three Months Ended June 30, |
| Six Months Ended June 30, | ||||||||||||
|
| 2023 |
|
|
| 2022 |
|
|
| 2023 |
|
|
| 2022 |
|
| ($ in millions) | ||||||||||||||
Net (loss) income | $ | (74.1 | ) |
| $ | 20.8 |
|
| $ | (70.9 | ) |
| $ | 47.5 |
|
Impairment of goodwill |
| 85.8 |
|
|
| — |
|
|
| 85.8 |
|
|
| — |
|
Income tax (benefit) expense |
| (10.6 | ) |
|
| 6.4 |
|
|
| (9.1 | ) |
|
| 15.1 |
|
Interest expense and amortization of debt discounts and fees |
| 10.3 |
|
|
| 0.1 |
|
|
| 19.8 |
|
|
| 0.1 |
|
Depreciation and amortization |
| 7.7 |
|
|
| 8.2 |
|
|
| 15.5 |
|
|
| 16.7 |
|
Unusual or nonrecurring items that are not typical of ongoing operations(1) |
| 2.6 |
|
|
| 4.1 |
|
|
| 4.9 |
|
|
| 6.1 |
|
Stock-based compensation |
| 2.6 |
|
|
| 1.2 |
|
|
| 4.1 |
|
|
| 2.5 |
|
Net income attributable to noncontrolling interests |
| (0.3 | ) |
|
| (0.7 | ) |
|
| (0.8 | ) |
|
| (1.3 | ) |
Gain on disposal or impairment of assets |
| (0.1 | ) |
|
| (0.4 | ) |
|
| (0.1 | ) |
|
| (0.5 | ) |
Stock-based compensation included in overhead allocation |
| — |
|
|
| 0.6 |
|
|
| — |
|
|
| 1.1 |
|
Adjusted EBITDA | $ | 23.9 |
|
| $ | 40.3 |
|
| $ | 49.2 |
|
| $ | 87.3 |
|
(1) | Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism defense; in 2022, they include costs associated with the strategic alternatives review. |
Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA | |||||||||||||||
|
|
|
| ||||||||||||
| Three Months Ended June 30, |
| Six Months Ended June 30, | ||||||||||||
|
| 2023 |
|
|
| 2022 |
|
|
| 2023 |
|
|
| 2022 |
|
| ($ in millions) | ||||||||||||||
Net cash provided by operating activities | $ | 9.6 |
|
| $ | 33.6 |
|
| $ | 39.2 |
|
| $ | 75.0 |
|
Interest expense, excluding amortization of debt discounts and fees |
| 10.1 |
|
|
| 0.1 |
|
|
| 19.3 |
|
|
| 0.1 |
|
Unusual or nonrecurring items that are not typical of ongoing operations(1) |
| 2.6 |
|
|
| 4.1 |
|
|
| 4.9 |
|
|
| 6.1 |
|
Change in assets and liabilities, excluding derivative instruments |
| 1.2 |
|
|
| (5.0 | ) |
|
| (15.0 | ) |
|
| (10.3 | ) |
Current portion of income tax expense |
| 0.7 |
|
|
| 7.6 |
|
|
| 1.9 |
|
|
| 16.5 |
|
Net income attributable to noncontrolling interests in continuing operations |
| (0.3 | ) |
|
| (0.7 | ) |
|
| (0.8 | ) |
|
| (1.3 | ) |
Stock-based compensation included in overhead allocation |
| — |
|
|
| 0.6 |
|
|
| — |
|
|
| 1.1 |
|
Other |
| — |
|
|
| — |
|
|
| (0.3 | ) |
|
| 0.1 |
|
Adjusted EBITDA | $ | 23.9 |
|
| $ | 40.3 |
|
| $ | 49.2 |
|
| $ | 87.3 |
|
(1) | Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism defense; in 2022, they include costs associated with the strategic alternatives review. |
Enhabit, Inc. and Subsidiaries Supplemental Information Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow | |||||||||||||||
|
|
|
| ||||||||||||
| Three Months Ended June 30, |
| Six Months Ended June 30, | ||||||||||||
|
| 2023 |
|
|
| 2022 |
|
|
| 2023 |
|
|
| 2022 |
|
| ($ in millions) | ||||||||||||||
Net cash provided by operating activities | $ | 9.6 |
|
| $ | 33.6 |
|
| $ | 39.2 |
|
| $ | 75.0 |
|
Capital expenditures for maintenance |
| (1.1 | ) |
|
| (0.3 | ) |
|
| (1.7 | ) |
|
| (2.6 | ) |
Other working capital adjustments |
| (0.5 | ) |
|
| (0.4 | ) |
|
| (1.0 | ) |
|
| (0.9 | ) |
Distributions paid to noncontrolling interests of consolidated affiliates |
| — |
|
|
| (0.2 | ) |
|
| (2.5 | ) |
|
| (0.7 | ) |
|
|
|
|
|
|
|
| ||||||||
Items non-indicative of ongoing operating performance: |
|
|
|
|
|
|
| ||||||||
Unusual or nonrecurring items that are not typical of ongoing operations(1) |
| 2.6 |
|
|
| 4.1 |
|
|
| 4.9 |
|
|
| 6.1 |
|
Stock-based compensation included in overhead allocation |
| — |
|
|
| 0.6 |
|
|
| — |
|
|
| 1.1 |
|
Adjusted free cash flow | $ | 10.6 |
|
| $ | 37.4 |
|
| $ | 38.9 |
|
| $ | 78.0 |
|
(1) | Unusual or nonrecurring items in 2023 include costs associated with nonroutine litigation and shareholder activism defense; in 2022, they include costs associated with the strategic alternatives review. |
FORWARD-LOOKING STATEMENTS
Statements contained in this press release which are not historical facts, such as those relating to future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All such estimates, projections, and forward-looking information speak only as of the date hereof, and Enhabit undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by Enhabit include, but are not limited to, our ability to execute on our strategic plans, regulatory and other developments impacting the markets for our services, changes in reimbursement rates, general economic conditions, our ability to attract and retain key management personnel and healthcare professionals, potential disruptions or breaches of our or our vendors’ information systems, the outcome of litigation, our ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures, and our ability to control costs, particularly labor and employee benefit costs. In addition, with respect to the Tax Matters Agreement (TMA) and the potential launch of a strategic alternative process, these factors include, our ability to receive Encompass Health Corporation’s approval to pursue a strategic transaction as required under the TMA and our ability to successfully pursue and complete a strategic transaction, as discussed above. Our Form 10-K and subsequent quarterly reports on Form 10-Q, each of which can be found on the Company’s website at http://investors.ehab.com and the SEC’s website at www.sec.gov, discuss other risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this press release. We urge you to consider all of the risks, uncertainties and factors identified above or discussed in such reports carefully in evaluating the forward-looking statements in this press release.
| Last Trade: | US$7.46 |
| Daily Change: | 0.19 2.61 |
| Daily Volume: | 320,851 |
| Market Cap: | US$375.090M |
November 06, 2024 August 06, 2024 July 01, 2024 May 08, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
